Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and
other diseases. Currently, more than 25 oncology drugs that target kinases have been …

The casein kinase I family of serine/threonine protein kinases is highly conserved from yeast
to humans. Until only recently, both the function and regulation of these enzymes remained …

Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature
of a major subset of primary human brain cancers. These mutations occur at a single amino …

A number of human cancers harbor somatic point mutations in the genes encoding isocitrate
dehydrogenases 1 and 2 (IDH1 and IDH2). These mutations alter residues in the enzyme …

Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and
secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, …

The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate
dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered …

DBA mice were chronically treated with nicotine by continuous intravenous infusion of 4.0
mg/kg/hr for 10 d. Drug-treated mice were tolerant to the acute effects of nicotine on locomotor …

Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive
in many human cancers and is thus a target for novel therapeutics. We have developed a …

Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion
of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide …

Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2-…